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ARTICLE
High-ﬁdelity CRISPR/Cas9- based gene-speciﬁc
hydroxymethylation rescues gene expression and
attenuates renal ﬁbrosis
Xingbo Xu1,2, Xiaoying Tan2,3, Björn Tampe 3, Tim Wilhelmi1,2, Melanie S. Hulshoff1,2,4, Shoji Saito3,
Tobias Moser 5, Raghu Kalluri6, Gerd Hasenfuss1,2, Elisabeth M. Zeisberg1,2 & Michael Zeisberg2,3
While suppression of speciﬁc genes through aberrant promoter methylation contributes to
different diseases including organ ﬁbrosis, gene-speciﬁc reactivation technology is not yet
available for therapy. TET enzymes catalyze hydroxymethylation of methylated DNA, reac-
tivating gene expression. We here report generation of a high-ﬁdelity CRISPR/Cas9-based
gene-speciﬁc dioxygenase by fusing an endonuclease deactivated high-ﬁdelity Cas9
(dHFCas9) to TET3 catalytic domain (TET3CD), targeted to speciﬁc genes by guiding RNAs
(sgRNA). We demonstrate use of this technology in four different anti-ﬁbrotic genes in
different cell types in vitro, among them RASAL1 and Klotho, both hypermethylated in kidney
ﬁbrosis. Furthermore, in vivo lentiviral delivery of the Rasal1-targeted fusion protein to
interstitial cells and of the Klotho-targeted fusion protein to tubular epithelial cells each
results in speciﬁc gene reactivation and attenuation of ﬁbrosis, providing gene-speciﬁc
demethylating technology in a disease model.
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Aberrant CpG island promoter methylation of select genesleads to silencing of these genes and thus contributes tovarious pathologies such as cancer, neuronal degenera-
tion, and organ ﬁbrosis1–3. Well-studied examples of such genes
are RASAL1 (which encodes for a Ras-GAP-like Ras-GTP inhi-
bitor, and hypermethylation of the RASAL1 promoter leads to
silencing of RASAL1 expression and increased RAS-GTP
activity)4–6 and KL1 (which encodes for Klotho, a transmem-
brane protein working as a co-receptor for ﬁbroblast growth
factor-23), both of which have been associated with cancer and
also ﬁbrogenesis:7–11 The RASAL1 promoter is consistently
hypermethylated in tissue ﬁbrosis including kidney, heart, and
liver and also in gastrointestinal cancers4–6,9,13. The extent of
RASAL1 promoter methylation correlates with progression of
kidney ﬁbrosis in patients and mice14, and rescue of RASAL1
transcription through transgenic overexpression attenuates pro-
gression of experimental ﬁbrosis in the kidney14. This suggests
that reversal of aberrant RASAL1 methylation and rescue of
RASAL1 expression are new therapeutic targets to inhibit pro-
gression of kidney ﬁbrosis. RASAL1 was originally identiﬁed as
one of three genes (including also EYA1 encoding for a member
of the eyes absent (EYA) family of proteins, which plays a key role
in the kidney development 15,16 and LRFN2, encoding for
leucine-rich repeat and ﬁbronectin type III domain-containing
protein, which functions in presynaptic differentiation17) in a
genome-wide methylation screen comparing normal and ﬁbrotic
kidney ﬁbroblasts, which were consistently downregulated and
hypermethylated in ﬁbrotic but not healthy ﬁbroblasts both in
humans and mouse4.
Hypermethylation of the KLOTHO promoter has been shown to
be associated with progression of various forms of cancer and to
correlate with kidney ﬁbrosis in both humans and experimental
ﬁbrosis mouse models18–22. In the kidney, Klotho is predominantly
expressed in tubular epithelial cells. Reversal of hypermethylated
Klotho promoter associated Klotho suppression by a lipophilic
anthraquinone compound, Rhein, has been demonstrated to ame-
liorate renal ﬁbrosis in unilateral ureter obstruction (UUO)-induced
ﬁbrotic kidney mouse model. This results through effectively
reducing aberrant DNMT1/3a expression and thereby maintaining
secreted and membrane Klotho levels22.
It has long been known that DNA methylation can be inhibited
through administration of nucleotide analogs such as 5′azacyti-
dine, which is incorporated into the DNA thereby causing DNA
damage and subsequent DNA repair by replacement with
unmethylated DNA. While nucleotide analogs are in clinical use
in several malignant diseases such as myelodysplastic syndrome
as demethylating therapies, they are highly unspeciﬁc and their
utility is limited to second line therapies due to side effects,
highlighting the need for gene-speciﬁc, less toxic demethylating
therapies.
In this regard, members of the ten-eleven translocation (TET)
family of zinc ﬁnger proteins (ZFPs) catalyze oxidation of
methylated cytosine residues (so-called hydroxymethylation),
which subsequently leads to replacement of methylated cytosine
residues with naked cytosine23. Both hydroxymethylated and
demethylated promoters result in re-expression of genes that had
been silenced through CpG promoter methylation. We previously
demonstrated that (1) TET3 is the predominant TET protein in
the kidney5, (2) kidney ﬁbrosis is associated with decreased TET3
expression5, and (3) induction of endogenous TET3 expression
leads to hydroxymethylation, demethylation, and thereby reacti-
vation of various genes, including RASAL1, within diseased kid-
neys and attenuates experimental kidney ﬁbrosis5,14. TET3 only
induces transcription of genes that had been previously methy-
lated, and it is recruited to select genes (including RASAL1)
through recognition of a common CXXC motif in proximity to
gene promoter CpG islands, providing enhanced speciﬁcity as
compared to nucleotide analogs. As opposed to silencing of
DNMTs, activation of TET enzymes is an active way of reducing
aberrant gene methylation. However, there are more than 9000
genes targeted by TET proteins within the human genome, sug-
gesting gene-speciﬁc delivery of TET as an attractive approach to
rescue expression of aberrantly methylated genes24.
Previous studies demonstrated that by fusion of the TET
methylcytosine dioxygenase catalytic domain (in which the
CXXC binding domain is lacking) to the programmable DNA-
binding domains of ZFPs or transcription activator-like effectors
(TALE), enhanced gene-speciﬁcity of hydroxymethylation and re-
expression of methylated genes could be achieved as compared to
globally increased TET expression25,26. However, utility of these
approaches was limited due to off-target effects, high labor
intensity, and lack of evidence for disease modifying activities
in vivo, revealing that a technique with further enhanced speci-
ﬁcity was needed.
Here we aimed to utilize both the high target speciﬁcity of
sgRNA-guided Streptococcus pyogenes dCas9 and the enzymatic
effectiveness of TET3. We demonstrate gene-speciﬁc targeting
and successful re-expression of hypermethylated genes RASAL1,
EYA1, LRFN2, and KLOTHO through all-in-one constructs in
which either dCas9 or high-ﬁdelity dCas9, respectively, is fused to
the TET3 catalytic domain which is speciﬁcally targeted to the
promoters of these genes by single-guide RNA (sgRNA). We
further systematically established viral targeting of different cell
populations in the kidney in vivo and demonstrate that by
expression of dCas9/dHFCas9-TET3CD-RASAL1-sgRNA in
kidney ﬁbroblasts and of dHFCas9-TET3CD-KLOTHO-sgRNA
in epithelial cells, ﬁbrosis is signiﬁcantly attenuated in a mouse
model of kidney ﬁbrosis. In summary, we show that CRISPR/
Cas9-based gene-speciﬁc hydroxymethylation can rescue gene
expression. This technology therefore has a broad application
spectrum and may be useful to combat other diseases induced by
aberrant gene methylation, such as various forms of cancer and
neurodegenerative diseases.
Results
Targeted hydroxymethylation rescues gene expression in vitro.
In order to generate a gene-speciﬁc hydroxymethylation system,
we created a chimeric hydroxymethylase by fusing the TET3
catalytic domain (TET3CD)24,27 to the C-terminal domain of a
double mutated Cas9 (dCas9), in which endonuclease catalytic
residues D10A and H840A have been mutated to avoid cutting of
the DNA (Figs. 1a, b, Supplementary Fig. 1)28–33. We next
introduced TET3CD (aa851–aa1795) to generate a hydro-
xymethylation vector (pLenti-dCas9-TET3CD) (Supplementary
Figs. 1, 2)24,34. We have also generated a control vector (pLenti-
dCas9-TETCDi) in which catalytic residue mutations H1077Y
and D1079A have been created to abolish the hydroxymethyla-
tion activity of TET3CD (Supplementary Fig. 2)35. As proof-of-
principle, we aimed to reactivate the genes RASAL1, EYA1,
LRFN2, and KLOTHO whose expressions are silenced due to
promoter hypermethylation in ﬁbrotic human renal ﬁbroblasts
and human tubular epithelial cells, respectively4,36,37. To identify
applicable sgRNA to enable speciﬁc targeting of the dCas9-
TET3CD fusion protein to the gene promoters, we designed
10 sgRNAs (ﬁve guiding RNAs targeting each strand) targeting
the RASAL1 promoter, six sgRNAs (three guiding RNAs targeting
each strand) targeting the EYA1 promoter, eight sgRNAs
(four guiding RNAs targeting each strand) targeting the LRFN2
promoter and the Klotho promoter, respectively. Those
sgRNAs were inserted into the pLenti-dCas9-TET3CD
vector to generate gene-speciﬁc demethylation constructs for
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RASAL1 (pLenti-dCas9-RASAL1-sgRNA1-10), EYA1 (pLenti-
dCas9-EYA1-sgRNA1-6), LRFN2 (pLenti-dCas9-LRFN2-
sgRNA1-8), and KLOTHO (pLenti-dCas9-TET3CD-KL-sgRNA1-
8). LacZ sgRNA38 was introduced into pLenti-dCas9-TET3CD
(pLenti-dCas9-LacZ-sgRNA) vector serving as control construct.
Upon establishing the demethylation constructs, we tested their
demethylation activities utilizing TK188 ﬁbrotic human renal
ﬁbroblasts with known robust CpG island promoter methylation
for RASAL1, EYA1, and LRFN2 and HK2 epithelial cells with
known CpG island promoter methylation for Klotho upon
stimulation with TGFβ1. Fibrotic ﬁbroblasts, which were treated
with dCas9-TET3CD-RASAL1-sgRNA2/3, showed signiﬁcant
reactivated RASAL1 expression (Fig.1c). Cells that were treated
with dCas9-TET3CD-EYA1-sgRNA1/3 showed reactivated EYA1
expression (Fig. 1d). Cells that were treated with dCas9-TET3CD-
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Fig. 1 Targeted hydroxymethylation of four different aberrantly methylated genes by dCas9-TET3CD fusion protein in human kidney cells. a Schematic
representing hypermethylated RASAL1 promoter region (upper panel) and reactivated RASAL1 expression through induction of RASAL1 promoter
hydroxymethylation by dCas9-TET3CD fusion protein in complex with a sgRNA binding to its target region (lower panel). b Schematic of domain structure
of the dCas9-TET3CD (upper panel) and dCas9-TETCDi (lower panel) fusion protein. c–e Locations for RASAL1/EYA1/LRFN2-sgRNAs are indicated by
thick lines with corresponding PAM in magenta within the human RASAL1/EYA1/LRFN2 gene locus, respectively. Human ﬁbrotic TK188 ﬁbroblasts were
transduced with lentivirus expressing demethylation constructs guided by RASAL1-sgRNAs 1–10, EYA1-sgRNA 1–6, LRFN2-sgRNA 1–8, or by LacZ control
sgRNA. Results were normalized to reference gene GAPDH. f, gMeDIP and hMeDIP analysis of TK188 cells were transduced with dCas9-TET3CD-RASAL1-
sgRNA3. The results were calculated relative to the input. h Bisulﬁte sequencing summary of promoter methylation status of the RASAL1 gene in TK188
cells transduced with demethylation constructs guided by RASAL1-sgRNA3, by LacZ control sgRNA or DNA treated with M.SssI serving as positive control.
Each data point represents the mean of three independent transduction experiments with error bars indicating the standard error of the mean for six or
more bisulﬁte sequencing results. i Locations for KL-sgRNAs are indicated by thick lines with corresponding PAM in magenta within the human KL gene
locus. Three days TGFβ1-treated HK2 cells were transduced with lentivirus expressing demethylation constructs guided by KL-sgRNAs 1–8 or by LacZ
control sgRNA. j, k MeDIP and hMeDIP analysis of HK2 cells were transduction with dCas9-TET3CD-KL-sgRNA2. The results were calculated relative to
the input. All data are presented as mean value; error bars represent S.D.; n= 3 independent biological replicates, n.s. not signiﬁcant; *p < 0.05, **p < 0.01,
***p < 0.001
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Restored expression does not occur with LacZ nor with the
respective pLenti-dCas9-TETCDi vectors, in which hydroxy-
methylation activity of TET3CD was abolished (Fig. 1c–e). HK2
epithelial cells showed reduced expression of Klotho upon TGFβ1
treatment, which was restored upon pLenti-dCas9-TET3CD-KL-
sgRNA1-2 vectors (Fig. 1i). To rule out the possibility that
demethylation is due to overexpression of TET3CD, we
performed experiments only using TET3CD vectors without
guiding RNA. No signiﬁcant gene induction was observed in any
of these 4 genes indicating that demethylation is not due to
overexpression of TET3CD (Supplementary Fig. 3). Among the
three tested genes in ﬁbroblasts, cells that were treated with
dCas9-TET3CD-RASAL1-sgRNA3 showed the highest induction
level which was comparable to RASAL1 mRNA expression in
control (non-ﬁbrotic) human kidney ﬁbroblasts.
We hence performed methylation- and hydroxymethylation-
speciﬁc MeDIP and hMeDIP assays (immunoprecipitation of
methylated or hydroxymethylated DNA, respectively, followed by
qPCR) of the RASAL1 promoter for dCas9-TET3CD guided by
RASAL1-sgRNA3, LacZ-sgRNA, and dCas9-TET3CDi guided by
RASAL1-sgRNA3, revealing that among those different vectors,
only dCas9-TET3CD-RASAL1-sgRNA3 signiﬁcantly induced
RASAL1 promoter hydroxymethylation and reduced methylation
(Fig. 1f, g). To determine if and which CpG sites could be
demethylated in the RASAL1 promoter region after expression of
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performed. In contrast to dCas9-TET3CD-LacZ-sgRNA trans-
duced cells, cells transduced with dCas9-TET3CD-RASAL1-
sgRNA3 demonstrated demethylation in the promoter region
between −114 to +1 (Fig. 1h, Supplementary Fig. 4), suggesting
this to be a “critical promoter region”. To gain single base-pair
resolution for hydroxymethylation within the critical region, we
performed glucosylation-mediated restriction enzyme sensitive
PCR (gRES-PCR) revealing that upon treatment with T4-BGT
and MspI the uncleaved RASAL1 PCR amplicon was only
detectable in the cells transduced with dCas9-TET3CD-RASAL1-
sgRNA3 (Supplementary Fig. 5d) but not in the other samples
(Supplementary Fig. 5b, c, e), conﬁrming site-speciﬁc hydro-
xymethylation of the RASAL1 promoter by dCas9-TET3CD-
RASAL1-sgRNA3. Upon establishing that dCas9-TET3CD-
RASAL1-sgRNA3 effectively induced RASAL1 CpG promoter
hydroxymethylation and demethylation and subsequent rescue of
RASAL1 expression, we identiﬁed all genes which were predicted
to be targeted by sgRNA3 via the online program CCTop39. We
hence performed qRT-PCR for these genes, but no signiﬁcant
difference in mRNA expression could be detected for any of the
predicted genes other than RASAL1 when comparing cells
transduced with dCas9-TET3CD-RASAL1-sgRNA3 with cells
transduced with dCas9-TET3CD-LacZ-sgRNA (Supplementary
Fig. 6, Supplementary Table 8). This suggests that none of these
predicted off-targeted genes was hypermethylated and hence they
were not affected by our demethylation system.
Just as for RASAL1, we rescued KL expression corresponding
with enhanced KL promoter hydroxymethylation and decreased
promoter methylation (Fig. 1j, k). We also performed qRT-PCR
for those genes that were predicted to be KL sgRNA2 off-targets.
Other than KL no signiﬁcant difference in mRNA expression
could be detected when comparing cells transduced with sgRNA2
with cells transduced with LacZ-sgRNA (Supplementary Fig. 7,
Supplementary Table 9).
In summary, we demonstrate successful targeted demethyla-
tion of 4 different aberrantly methylated gene promoters
(RASAL1, EYA1, LRFN1, and KL) and in two different cell types
(ﬁbroblasts and epithelial cells) through lentiviral delivery of a
construct encoding a fusion protein of dCas9-TET3CD, which is
targeted to the promoter CpG through speciﬁc single-guide RNA.
Notably, we realized that demethylation proteins guided by
sgRNAs that are targeting the DNA antisense strand are more
efﬁcient as compared to those where the DNA sense strand was
targeted.
In order to explore the possibility of utilizing this demethyla-
tion system in mice in vivo, we next tested our system in primary
mouse kidney ﬁbroblasts (mKFs) and in mouse renal tubular
epithelial cells (MCT cells), where Rasal1 and Kl expressions are
reduced, respectively, via promoter hypermethylation by pro-
longed exposure to TGFβ1 treatment (Fig. 2a–f, Supplementary
Fig. 8a, b)4,5. We designed eight different sgRNAs (four sgRNAs
targeting each strand) targeting the Rasal1 promoter and six
different sgRNAs (all sgRNAs targeting antisense strand)
targeting the Kl promoter, and introduced them into a pLenti-
dCas9-TET3CD vector (pLenti-dCas9-TET3CD-Rasal1-sgRNA1-
8 or pLenti-dCas9-TET3CD-Kl-sgRNA1-6) to transduce 10 days
TGFβ1-treated mKFs or three days TGFβ1-treated MCT cells,
respectively. We identiﬁed that three of the constructs (dCas9-
TET3CD-Rasal1-sgRNA2-4) rescued Rasal1 expression (Fig. 2a,
Supplementary Fig. 8d) and three of the constructs (dCas9-
TET3CD-Kl-sgRNA1-3) restored Kl expression (Fig. 2b). More-
over, rescued Rasal1 and Kl expression corresponded with
enhanced hydroxymethylation and attenuated promoter methy-
lation for both genes (Fig. 2a–f). Bisulﬁte sequencing identiﬁed
−323 bp to −179 bp as the critical region within the murine
Rasal1 promoter which has been demethylated (Fig. 2d,
Supplementary Fig. 9) and −101 bp to +98 bp as the critical
region within the murine Kl promoter which has been effectively
demethylated (Fig. 2f, Supplementary Fig. 10).
In order to test off-target effects (a problem immanent to the
Cas9 technology, which has thus far limited therapeutic utility40),
we performed chromatin immunoprecipitation followed by
sequencing (ChIP-seq) for dCas9-TET3CD-Rasal1-sgRNA4
binding sites in mKFs. Our data reveal the targeted region of
the Rasal1 promoter and a large number of 159 off-target binding
sites within 48 different genes (Table 1). Importantly, these off-
target genes included genes with known pro-ﬁbrotic effects
(which are commonly silenced by promoter methylation in
normal tissue) such that therapeutic efﬁcacy by rescue of (anti-
ﬁbrotic) RASAl1 could be counteracted by newly induced
expression of pro-ﬁbrotic genes through our dCas9-TET3CD
construct. We therefore next aimed to improve our technique to
reduce off-target effects. Among all methods to reduce off-target
effects of Cas9, the use of high-ﬁdelity CRISPR-spCas9 has been
shown to be the most efﬁcient41. We hence introduced catalytic
domain deactivation amino acid mutations (D10A and H840A)
into high-ﬁdelity spCas9 to abolish its cleavage properties and we
Fig. 2 dCas9-TET3CD and dHFCas9-TET3CD fusion proteins induce targeted Rasal1/ Kl promoter demethylation in mouse kidney cells and dHFCas9-
TET3CD largely reduced off-target effects. a Locations for Rasal1-sgRNAs are indicated by thick lines with corresponding PAM in magenta within the
mouse Rasal1 gene locus. 10 days TGFβ1-treated mKF were transduced with dCas9-TET3CD-Rasal1-sgRNAs1-8 or by LacZ control sgRNA. b Locations for
Klotho-sgRNAs are indicated by thick lines with corresponding PAM in magenta within the mouse Klotho gene locus. Three days TGFβ1-treated MCT were
transduced with dCas9-TET3CD-Klotho-sgRNAs1-6 or by LacZ control sgRNA. c MeDIP and hMeDIP analysis of TGFβ1-treated mKF were transduced with
dCas9-TET3CD-Rasal1-sgRNA4. d Bisulﬁte sequencing summary of promoter methylation status of the Rasal1 gene in TGFβ1-treated cells transduced with
dCas9-TET3CD-Rasal1-sgRNA4 or by LacZ control sgRNA. eMeDIP and hMeDIP analysis of TGFβ1-treated MCT cells transduced with dCas9-TET3CD-Kl1-
sgRNA2 or with LacZ control sgRNA. f Bisulﬁte sequencing summary of promoter methylation status of the Klotho gene in TGFβ1-treated MCT cells
transduced with dCas9-TET3CD-sgRNA2 or by LacZ control sgRNA. g Schematic of domain structure of the dHFCas9-TET3CD fusion protein. h TGFβ1-
treated mKFs were transduced with dCas9/dHFCas9-TET3CD-Rasal1-sgRNA4 or LacZ control sgRNA (left panel). TGFβ1-treated MCT cells were
transduced with dCas9/dHFCas9-TET3CD-Klotho-sgRNA2 or LacZ control sgRNA (right panel). iMeDIP-qPCR analysis of TGFβ1-treated mKFs transduced
with dCas9/dHFCas9-TET3CD-Rasal1-sgRNA4 or LacZ control sgRNA (left panel) and TGFβ1-treated MCT cells transduced with dCas9/dHFCas9-
TET3CD-Klotho-sgRNA2 or LacZ control sgRNA (right panel). j Venn diagram summarizes the common off-targets identiﬁed by ChIP-seq analysis between
dCas9-TET3CD and dHFCas9-TET3CD transduced mKF (left panel). Tracks indicate the binding regions and the enrichment of dCas9/dHFCas9-TET3CD-
Rasal1/Klotho/LacZ sgRNA protein-RNA complexes in mKF cells as visualized in the IGV browser (right panel). Genomic coordinates are shown below the
tracks (build mm9). All data are presented as mean value; error bars represent S.D, n= 3 independent biological replicates, n.s. not signiﬁcant, *p < 0.05,
**p < 0.01, ***p < 0.001. qRT-PCR results were normalized to reference gene Gapdh. MeDIP and hMeDIP results were calculated relative to input. For
bisulfate sequencing each data point represents the mean of three independent biological replicates with error bars indicating the standard error of the
mean for six or more bisulﬁte sequencing results
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05766-5 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3509 | DOI: 10.1038/s41467-018-05766-5 | www.nature.com/naturecommunications 5
generated a new dHFCas9-TET3CD demethylation construct
(Fig. 2g, Supplementary Fig. 11).
We used mouse Rasal1 sgRNA4 and Kl sgRNA2 (which
effectively induced gene expression in dCas9-TET3CD con-
structs) to generate dHFCas9-TET3CD-Rasal1-sgRNA4 and
dHFCas9-TET3CD-Kl-sgRNA2 and transduced them into mKFs
or MCT cells, respectively. Both Rasal1 and Klotho expressions
were signiﬁcantly reactivated to the same level as induced by the
dCas9-TET3CD vectors (Fig. 2h). Furthermore, rescued Rasal1
and Kl gene expression corresponded with attenuated promoter
Table 1 Off-target genes identiﬁed by ChIP-sequencing analysis
Targets of dCas9-TET3CD-Rasal1-sgRNA4
Chrom Start End Score ThickStart ThickEnd ItemRGB BlockCount Gene symbol
1 chr5 114153013 114153177 65 6.52912 11.72342 6.56068 89 1700069L16Rik
2 chr12 112968908 112969072 47 5.59639 9.73582 4.71895 68 2810002N01Rik
3 chr16 57391581 57391772 173 9.89721 23.05536 17.33657 48 2610528E23Rik
4 chr6 67692952 67693120 140 10.66121 19.54378 14.08762 37 abParts
5 chr8 125333034 125333227 47 5.59639 9.73582 4.71895 96 Acsf3
6 chr2 33906296 33906460 65 6.52912 11.72342 6.56068 112 AK048710
7 chr6 4764451 4764703 65 6.52912 11.72342 6.56068 92 AK076963
8 chr7 69254460 69254632 180 12.43808 23.6066 18.03127 30 AK086712
9 chr16 50557448 50557617 30 4.66366 7.81498 3.03828 84 AK144624
10 chr5 4053134 4053342 47 5.59639 9.73582 4.71895 104 Akap9
11 chr3 126852658 126852848 59 6.87729 10.96568 5.9056 56 Ank2
12 chr6 86698604 86698768 47 5.59639 9.73582 4.71895 82 Anxa4
13 chr1 50872914 50873114 465 23.98771 52.41908 46.51371 49 BC029710
14 chr17 13745750 13745921 114 4.18092 16.85615 11.47872 45 BC068229
15 chr10 58926851 58927510 247 36.82354 254.31743 247.07439 36 Ccdc109a
16 chr10 94156808 94156973 105 8.39458 15.86543 10.50555 90 Ccdc41
17 chr11 51843853 51844017 30 4.66366 7.81498 3.03828 55 Cdk13
18 chr11 12213679 12213882 65 6.52912 11.72342 6.56068 45 Cob1
19 chr7 26797237 26797401 76 7.92883 12.87339 7.67306 27 Cyp2b6
20 chr3 102939715 102939879 47 5.59639 9.73582 4.71895 114 Dennd2c
21 chr5 121098768 121099300 840 1.56069 13.73752 8.49179 341 Rasal1
22 chr14 8703442 8703750 40 6.77979 9.17137 4.05255 190 Flnb
23 chr7 34880923 34881149 150 11.29756 20.53988 15.0373 140 Gm12776
24 chr6 142752466 142752630 47 5.59639 9.73582 4.71895 76 Gm766
25 chr8 96357751 96357949 105 8.39458 15.86543 10.50555 95 Gnao1
26 chr5 104423124 104423288 65 6.52912 11.72342 6.56068 70 Hsd17b11
27 chr13 13846763 13846961 65 6.52912 11.72342 6.56068 82 Lyst
28 chr2 4930750 4931328 282 15.85643 33.99368 28.26957 289 Mcm10
29 chr18 7609200 7609768 168 11.19277 22.41256 16.85413 149 Mpp7
30 chr13 100159145 100159461 84 7.46185 13.7689 8.49179 232 Mrps27
31 chr10 6271609 6271773 84 7.46185 13.7689 8.49179 76 Mthfd1l
32 chr14 58173518 58173682 84 7.46185 13.7689 8.49179 94 N6amt2
33 chr15 95099096 95099260 65 6.52912 11.72342 6.56068 142 Nell2
34 chr9 121151 121315 47 5.59639 9.73582 4.71895 111 Nlrp4g
35 chr7 24212257 24212603 213 13.05824 26.95684 21.33005 163 Nlrp5
36 chr12 83086950 83087140 47 5.59639 9.73582 4.71895 35 Pcnx
37 chr3 96646134 96646506 65 6.52912 11.72342 6.56068 181 Pdzk1
38 chr3 152449257 152449918 190 12.12551 24.66862 19.07566 340 Pigk
39 chr9 66725484 66725736 84 7.9959 13.71865 8.4867 126 Rab8b
40 chr4 120536872 120537036 84 7.46185 13.7689 8.49179 82 Rims3
41 chr17 8149373 8149587 47 5.59639 9.73582 4.71895 57 Rsph3a
42 chr4 112068812 112069093 213 13.05824 26.95684 21.33005 143 Skint9
43 chr6 142181926 142182108 378 19.58736 43.71904 37.89215 36 Slc21a7
44 chr1 57911770 57911934 47 5.59639 9.73582 4.71895 35 Spats21
45 chr10 5264302 5264480 47 6.52912 11.72342 6.56068 99 Syne1
46 chr5 64639102 64639266 65 6.52912 11.72342 6.56068 66 Tbc1d1
47 chr4 74361648 74361927 187 13.99224 24.4904 18.76297 145 Tmem56
48 chr1 43834505 43834730 65 6.52912 11.72342 6.56068 124 Uxs1
Targets of dHFCas9-TET3CD-Rasal1-sgRNA4
Chrom Start End Score ThickStart ThickEnd ItemRGB BlockCount Gene symbol
1 chr1 50872919 50873111 322 19.47483 38.10745 32.22037 39 BC029710
2 chr17 13745609 13745912 88 3.17695 14.27044 8.84702 170 BC068229
3 chr10 58926856 58927475 359 23.74614 193.00722 185.91823 82 ccdc109a
4 chr14 8703110 8703279 73 8.12621 12.74668 7.36305 122 Flnb
5 chr7 34880926 34881147 169 13.16969 22.59302 16.90299 132 Gm12776
6 chr5 121098997 121099271 1273 1.52457 12.67083 7.3371 425 Rasal1
7 chr3 120952807 120952979 152 11.73355 20.8748 15.21403 37 Tmem56
8 chr10 5264302 5264480 47 5.59639 9.73582 4.71895 57 Syne1
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methylation to the same level as induced by the dCas9-TET3CD
vectors (Fig. 2i). To compare off-target binding sites between
dCas9-TET3CD and dHFCas9-TET3CD, we performed ChIP-seq
on cells transfected with dCas9-TET3CD-LacZ-sgRNA/-Rasal1-
sgRNA4, or dHFCas9-TET3CD-LacZ-sgRNA/-Rasal1-sgRNA4.
Using this approach, only eight genes were common for both
dCas9-TET3CD and dHFCas9-TET3CD (Table 1), besides 40
peaks speciﬁc only for dCas9-TET3 where many of the off-target
peaks showed quite high binding levels, as deﬁned by the peak
height relative to on-target peaks after subtracting dCas9-
TET3CD-LacZ-sgRNA reads at that site (Fig. 2j, Table 1).
RASAL1 knockdown aggravates kidney ﬁbrosis in vivo. To
perform proof-of principle experiments for a therapeutic efﬁcacy
of Rasal1 demethylation constructs, we next generated a Rasal1
knockout mouse model to validate that loss of Rasal1 is pro-
ﬁbrotic. It has been demonstrated by different research groups
that ﬁbrosis in the kidney, heart and liver, and also gastro-
intestinal cancers are associated with RASAL1 promoter hyper-
methylation, and that RASAL1 promoter hypermethylation leads
to decreased RASAL1 expression4–6,9,13. Also, the extent of
RASAL1 promoter methylation correlates with progression of
kidney ﬁbrosis in patients and mice14, and rescue of RASAL1
transcription through transgenic overexpression attenuates
experimental ﬁbrosis in the kidney14. However, whether loss of
Rasal1 expression per se contributes to kidney ﬁbrosis has not yet
been addressed.
We therefore generated Rasal1tm1a/tm1a mice that harbor a
gene-trap DNA cassette consisting of a splice acceptor site, an
internal ribosome entry site and a β-galactosidase reporter,
inserted into the second intron of the gene as described
extensively in the methods section (Fig. 3a and Supplementary
Fig. 12). In these mice Rasal1 expression is reduced by 80% on
mRNA and protein level as compared to wild-type littermate
control mice (Fig. 3b, c). Kidneys of Rasal1tm1a/tm1a mice
appeared unchanged as compared to wild-type littermate control
mice under baseline condition. However, after challenge with
UUO, a model of obstructive nephropathy, which results in
severe kidney ﬁbrosis through increased parenchymal pressure,
ensuing ischemia, tubular epithelial cell death, and inﬂammation
7 days after surgery. Rasal1tm1a/ tm1a mice displayed signiﬁcantly
higher levels of kidney ﬁbrosis as compared to wild-type
littermate controls, associated with higher levels of Collagen-1
deposition and abundance of a-SMA-positive ﬁbroblasts (Fig. 3d).
Viral delivery mode affects cellular targeting in vivo. After
establishing that lack of Rasal1 aggravates kidney ﬁbrosis and in
light of known causality of lack of Klotho as another contributor
to kidney ﬁbrosis and importantly because both genes are
silenced by hypermethylation during kidney ﬁbrosis, we decided
to test if targeted hydroxymethlation of Rasal1 and Klotho,
respectively, ameliorates kidney ﬁbrosis in vivo. Because Rasal1 is
primarily expressed in ﬁbroblasts and Klotho in tubular epithelial
cells, we ﬁrst established if different modes of lentiviral delivery
impact what cells are primarily targeted.
We therefore used green and red ﬂuorescence protein (GFP
and RFP) labeled control lentivirus to transduce kidneys by
different delivery routes. Transduction efﬁciency was > 95% in
mouse kidney ﬁbroblasts and > 95% in mouse kidney epithelial
cells in vitro (Fig. 4a, b). Next, we analyzed which cells are
targeted in vivo by testing four different delivery methods (using
108TU/80 μl virus particles each) in both healthy and UUO
kidneys: via the renal artery, intraparenchymal (4 sites with 20 µl/
site), via the renal vein, and via retrograde infusion into the
ureter. Ten days after virus injection, mice were sacriﬁced and
GFP and RFP expression was visualized by immunohistochem-
istry using antibodies against GFP and RFP, respectively
(Fig. 4c–f). Injection of lentivirus into the renal artery transduced
the fewest cells overall among all four techniques in both healthy
and UUO kidneys (Fig. 4c). Venous injection leads to transduc-
tion of interstitial cells (Fig. 4e), albeit to a lower extent as
compared to intraparenchymal injection (Fig. 4d). In contrast,
retrograde injection into the ureter predominantly transduced
tubular epithelial cells with high efﬁcacy (Fig. 4f).
In order to quantify percentage of transduced ﬁbroblasts we
next performed further analysis by double labeling of α-smooth
muscle actin (αSMA)-positive ﬁbroblasts and GFP. Ten days after
lentiviral intraparenchymal CMV-GFP construct delivery and
UUO surgery, an average of 46% of all αSMA-positive ﬁbroblasts
were also positive for GFP indicating successful transduction
(Fig. 4g).
Hydroxymethylation of Rasal1 and Klotho improves kidney
ﬁbrosis. To test the efﬁcacy of the established dCas9-TET3CD-
Rasal1-sgRNA and dCas9-TET3CD-Kl-sgRNA systems in vivo,
we utilized the mouse model of UUO. This model displays robust
Rasal1 promoter methylation within interstitial ﬁbroblasts and
Klotho methylation in tubular epithelial cells, resulting in tran-
scriptional suppression of Rasal1 and Klotho, which causes dis-
ease progression4,5. Based on our previous results which
demonstrated effective lentiviral transduction of kidney inter-
stitial cells upon vector delivery through intraparenchymal
injection and of epithelial cells upon vector delivery through
retrograde ureter infusion, we ﬁrst injected lentivirus harboring
either dCas9-TET3CD-/Rasal1 sgRNA4 or dHFCas9-TET3CD-/
Rasal1 sgRNA4 with dCas9-TET3CD-LacZ-sgRNA or dHFCas9-
TET3CD-LacZ-sgRNA as controls, respectively, into the renal
parenchyme of UUO-challenged and contralateral control kid-
neys (Fig. 5a, b).
Restored Rasal1 expression upon UUO was observed exclu-
sively in mice which received either dCas9-TET3CD-Rasal1-
sgRNA4 or dHFCas9-TET3CD-Rasal1-sgRNA4, but not in mice
injected with the dCas9/dHFCas9-TET3CD-LacZ-sgRNA control
vectors (Fig. 5c, d). Increased Rasal1 expression correlated with
increased Rasal1 hydroxymethylation and reduced methylation
(Fig. 5e, f). Most importantly, renal ﬁbrosis, accumulation of
ﬁbroblasts and type I collagen were signiﬁcantly attenuated in
dCas9/dHFCas9-TET3CD-Rasal1-sgRNA4 treated mice, but not
in mice administered with the dCas9/dHFCas9-TET3CD-LacZ-
sgRNA control vectors (Fig. 5g–j). Interestingly, even though
Rasal1 hydroxymethylation and restoration of Rasal1 expression
was equally effective, attenuation of kidney ﬁbrosis was almost
50% and thereby more effective in dHF- as compared to less than
30% in dCas9-TET3CD-Rasal1-sgRNA treated mice (Fig. 5c–j),
which is likely due to the reduction of off-target effects in the
dHFCas9-TET3CD as compared to the dCas9-TET3CD system
(Fig. 2j).
After establishing that dHFCas9-TET3CD is superior to the
dCas9-TET3CD system, we continued to use the dHFCas9-
TET3CD system for targeted hydroxymethylation of Klotho in
tubular epithelial cells in order to test its anti-ﬁbrotic potential
in vivo. To target methylated Klotho in tubular epithelial cells, we
performed retrograde injection of dHFCas9-TET3CD-Klotho-
sgRNA and dHFCas9-TET3CD-LacZ-sgRNA control viruses into
the ureters of UUO-challenged and of contralateral control
kidneys and analyzed the kidneys after 10 days (Fig. 6a, b).
Similar as with Rasal1, Klotho expression was successfully
restored to ~50% of the physiological level by dHFCas9-
TET3CD-Klothos-gRNA but not with LacZ-sgRNA and restora-
tion correlated with reduced Klotho promoter methylation levels
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(Fig. 6c–f). Kidney ﬁbrosis was signiﬁcantly reduced by 25.4% by
dHFCas9-Klotho-sgRNA as compared to dHF-TET3CD-LacZ-
sgRNA injection (Fig. 6f), and this reduction in ﬁbrosis correlated
with blunted accumulation of ﬁbroblasts and of type I Collagen
(Fig. 6g, h), correlating with Klotho demethylation and rescued
Klotho expression.
Discussion
In this study, we provide proof-of-principle that by using a novel
dCas9/dHFCas9-TET3CD all-in-one fusion protein approach,
single methylated genes can be speciﬁcally targeted and tran-
scriptionally reactivated in vitro as well as in vivo in a disease
model. Based on the example of four different genes (RASAL1,
EYA1, LRFN2, and KL) that are known to be hypermethylated in
speciﬁc cell types or upon stimulation with TGFβ1, we demon-
strate that targeted TET3-mediated hydroxymethylation is a
feasible, reliable, and fast technology which results in demethy-
lation and transcriptional reactivation of these genes. Because we
also demonstrate that use of the mutated wild-type SpCas9 in this
technology results in substantial off-target effects we developed a
new high-ﬁdelity Cas9-based approach which reduced off-target
genes by 85%. The relevance of reduction of off-target genes was
proven by testing our gene-speciﬁc demethylation technologies in
a disease model in vivo, which to our knowledge has not been
done before.
Among the four genes for which we established gene-speciﬁc
hydroxymethylation vectors, we selected Rasal1 and Klotho for
in vivo studies, as both genes have been well studied in context
of kidney ﬁbrosis in both human and mouse models: Klotho has
been shown to be hypermethylated and transcriptionally
silenced in kidney ﬁbrosis patients and in corresponding mouse
models, and lack of Klotho is causally linked to kidney ﬁbrosis
in mice. Rasal1 has been shown to be transcriptionally
silenced and hypermethylated in both human and mouse kid-
ney ﬁbrosis. Because the causality between Rasal1 and kidney
ﬁbrosis had not yet been addressed, we generated Rasal1
knockout mice in which Rasal1 expression was reduced by 70%.
In these mice, kidney ﬁbrosis was substantially increased upon
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Fig. 3 Rasal1 gene disruption results in aggravated ﬁbrosis level in the UUO model. a Schematic of knockout-ﬁrst strategy for Rasal1 gene. The gene trapping
LacZ cassette is alternatively spliced with exon 2 mediated by a splicing acceptor (SA). A promoter-driven Neomycin cassette is inserted after LacZ. The
targeted exon 3 and 4 are ﬂanked by loxP sites. Black arrows indicate the location of genotyping primers. b qRT-PCR analysis shows the Rasal1 mRNA
expression in homozygous mice are signiﬁcantly reduced as compared with wild-type mice, while there is no signiﬁcant reduction in heterozygous mice.
The data are presented as mean value, error bars represent S.D., n.s. not signiﬁcant, ***p < 0.001. c Western blot analysis shows the RASAL1 protein
expression is largely decreased in homozygous mice as compared with wild-type mice. d Kidney sections of wild type and homozygous Rasal1tm1a mutant
mouse which were either sham controls (CL) or challenged with UUO were stained for Masson’s Trichrome (MTS) (representative light microscopy
images are shown in the top row), Collagen-1 or α-SMA (representative confocal images are shown in the middle and bottom row, respectively.) (Scale
bars: 25 μm or 50 μm). Quantiﬁcation of the percentage of total interstitial ﬁbrosis and immunostained positive cells in each group are depicted (data are
presented as mean value, error bars represent S.E.M., # not signiﬁcant, ****p < 0.0001)
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Predominant expression of Rasal1 occurs in kidney ﬁbroblasts
and of Klotho in tubular epithelial cells. Both cell types are
separated by a basal membrane. Because it has been shown that
lentiviral constructs do not cross basal membranes42, we estab-
lished different routes of lentiviral delivery to primarily target
interstitial cells (via parenchymal injection) or epithelial cells (via
the ureter). By these respective modes of injection we were able to
speciﬁcally reactivate Klotho expression in tubular epithelial cells
by dHFCas9-TET3CD-Klotho-sgRNA and Rasal1 expression in
interstitial cells by dCas9/dHFCas9-TET3CD-Rasal1-sgRNA
constructs in the UUO mouse model of kidney ﬁbrosis and to
ameliorate kidney ﬁbrosis. Interestingly, the therapeutic anti-
ﬁbrotic effect of dCas9-TET3CD-Rasal1-sgRNA construct was
much smaller (less than 30% ﬁbrosis reduction) as compared to
the dHFCas9-TET3CD-Rasal1-sgRNA (almost 50% reduction in
total interstitial ﬁbrosis) despite a complete reactivation of Rasal1
expression by both constructs. It appears likely that this is due to
off-target effects of dCas9-TET3CD which reactivated pro-
ﬁbrotic genes Anxa4, and Nlrp5 (off-targeted by dCas9-
TET3CD but not by dHFCas9-TET3CD, Table 1) along with
Rasal1, thus limiting the therapeutic effect and highlighting the
need for the use of high-ﬁdelity Cas9 in this context.
In general, by fusing dCas9 with the TET3 catalytic domain, we
achieved superior speciﬁcity and reached a more extended region
of demethylation from the target site as compared to previous
Zinc ﬁnger and TALE-based approaches. Previous studies showed
that TET3 mediates hydroxymethylation of cytosine bases (e.g.,
within the Rasal1 promoter) followed by consecutive Tdg-
mediated base excision, and subsequent replacement with naked
cytosine14. siRNA-mediated depletion of Tdg effectively pre-
vented Rasal1 demethylation, suggesting that Tdg is needed for
the return to baseline gene expression upon hydroxymethyla-
tion14. Our study is in line with previous reports which demon-
strated gene-speciﬁc reactivation of epigenetically silenced genes
within cultured cells using dCas9-p300, dCas9-LSD1, dCas9-
VP64, and dCas9-TET1CD fusion constructs in vitro28–30,43,44.
Unlike our approach those studies did not use an all-in-one
fusion protein but two individual components, which are only
functional when both are delivered and expressed simultaneously
in the same cell, thus thereby limiting their utility in vivo.
CMV-RFP
RFP: A. renalis EGFP: parenchym











































































































Fig. 4 In vivo gene delivery to mouse kidney by Lentivirus transduction. a, b Immunoﬂuorescence pictures show that mouse kidney ﬁbroblasts and kidney
epithelial cells were efﬁciently transduced with lentivirus containing a RFP (a) or EGFP (b) gene, respectively. c–f Immunohistochemistry pictures show
RFP-/EGFP-positive cells in kidney sections which were transduced with lentivirus containing RFP (c, e) or EGFP (d, f) through different delivery routes:
renal artery (c), parenchyma (d), renal vein (e), and infusion into retrograde ureter (f) with 80 μl (108TU) virus particles for each method. n= 6 in each
injection group. g Representative confocal photomicrographs of UUO kidneys transduced with GFP-labeled lentivirus via parenchymal injection. The
sections were double stained for GFP (in green) and myoﬁbroblast marker α-SMA (in red). Nuclei were counterstained with DAPI (in blue). The box-
whisker plot (right panel) shows the percentage of GFP and α-SMA double positive cells out of all α-SMA-positive cells. n= 3 mice
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Our study is further in line with a very recent report, where a
demethylating system based on dCas9 is fused to the repeating
peptide GCN4, which recruits an anti-GCN4 single-chain vari-
able fragment (scFv) fused to the effector domain of TET1CD45.
This system was successfully introduced into the embryonic
mouse brain by in utero electroporation and thereby reactivated
expression of speciﬁc genes including Gfap in vivo. Our appli-
cation is in contrast by lentiviral delivery and is made possible
through a considerably smaller size of the construct in our study
as compared to constructs utilized in that study and thus presents
a more feasible therapeutic approach in vivo as compared to
electroporation-based gene delivery. Thus, although there are
previous reports with respect to gene-speciﬁc demethylation both
in vitro and in vivo, to our knowledge, this study is the ﬁrst to
describe an effective CRISPR-based epigenetic therapy in a dis-
ease model. Unlike all previously published reports where only
catalytic domain of TET1 or TET2 have been fused with DNA-
binding domains ZNF, TALE, or dCas925,26,45, to our knowledge
dCas9-TET3CD
dHFCas9-TET3CD
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we are the ﬁrst to validate gene-speciﬁc demethylation by
TET3CD by the use of dCas9-TET3CD.
Even more importantly, none of the previous studies used a
high-ﬁdelity Cas9. Off-target effects largely hinder the utility of
CRISPR/Cas9 technology therapeutically. Through substitution of
four amino acids, Kleinstiver and his colleagues developed a high-
ﬁdelity Cas9, which abolishes the redundant energetics of
SpCas9-sgRNA with the consequence of diminished off-target
effects41. Thus, as long as number of off-target genes is kept low
through the use of HFCas9, adverse effects of our strategy in cells
other than the target cells are unlikely since only methylated
genes which were originally actively transcribed within target cells
can be reactivated. This provides a conceptual advantage over
other therapies based on e.g. AAV-delivered overexpression
constructs where the targeting of speciﬁc cell types still remains a
challenge.
Methods
Plasmids. The sgRNA sequences (RASAL1, EYA1, LRFN2, KL, Rasal1, and Kl)
were designed by the online tool Blueheronbio (Origene, Herford, Germany). The
control LacZ sgRNA sequence was the same as previously used38. The sgRNA
sequences (Supplementary Table 1) were inserted into the pLenti-Cas-Guide
plasmid (Origene, Herford, Germany) with BamHI and BsmBI restriction sites to
generate pLenti-Cas-sgRNA (RASAL1, EYA1, LRFN2, KL, Rasal1, and Kl) con-
structs and conﬁrmed by DNA sequencing. The wild-type Cas9 open reading frame
was removed from the vector with Age1 and Not1 restriction sites. The plasmids
encoding H840A SpCas9 and encoding high-ﬁdelity SpCas9-HF4 were gifts from
Jennifer Doudna and Keith Joung, respectively. (Addgene plasmids #3931646 and
#7224941.) The pLenti-dCas9-sgRNA gene demethylation constructs were gener-
ated by cloning H840 SpCas9 in frame into the digested pLenti-sgRNA vectors by
PCR using Phusion high-ﬁdelity DNA polymerase (NEB, Ipswich, USA) with Age1
(5′) and Xba1, Not1 (3′) restriction sites with two NLS (nuclear localization signal)
peptides at the N- and C-terminus each with a primer pair that introduced the
D10A mutation30 (Supplementary Table 6). The TET3CD (catalytic domain, aa
850- 1795)24 was ampliﬁed from a human TET3 ORF (Origene, Herford, Ger-
many) with a primer pair which introduced Age1, a start codon, Xba1, a Gly- Gly-
Gly- Ser- Gly linker (5′), and Not1 (3′) and then inserted into the digested pLenti-
dCas-LacZ vector to generate pLenti-dCas9-TET3CD-LacZ. The sequence and the
coding frame for dCas9 and for TET3CD were conﬁrmed by DNA sequencing and
by western blot (Supplementary Fig. 1). The ﬁnal constructs pLenti-dCas9-
TET3CD-sgRNA (RASAL1, EYA1, LRFN2, KL, Rasal1, and Kl) were generated by
removing TET3CD from pLenti-dCas9-TET3CD-LacZ, subsequently inserted into
pLenti-dCas9-sgRNA (RASAL1, EYA1, LRFN2, KL, Rasal1, and Kl) with Xba1 and
Not1 restriction sites. The primer sequences used for PCR cloning are listed in
Supplementary Table 2.
DNA isolation, MeDIP, and hMeDIP assay. Animal tissues or cell pellets were
lysed by DNA lysis buffer (Qiagen, Hilden, Germany) and precipitated and puriﬁed
using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol. Prior to immunoprecipitation, genomic DNA was
sonicated (Qsonica, Newtown, USA) to produce DNA fragments ranging in size
from 200 to 1000 bp, with a mean fragment size of around 300 bp. Methylated
DNA was captured using Methylamp Methylated DNA Capture Kit (Epigentek,
Farmingdale, USA). In total 1.0 µg of fragmented DNA was applied in every
antibody-coated well and incubated at room temperature on a horizontal shaker
for 2 h. The immunoprecipitated DNA was released by proteinase K. The DNA was
eluted and adjusted to a ﬁnal volume of 100 µl with nuclease-free water. For each
sample, an input vial was included using total sonicated DNA as loading control.
Hydroxymethylated DNA was captured using EpiQuick Hydroxymethylated
Immunoprecipitation (hMeDIP) Kit (Epigentek, Farmingdale, USA) according to
the manufacturer’s protocol. A volume of 0.5 μg of sonicated DNA was added to
each antibody-coated well and incubated at room temperature on a horizontal
shaker for 90 min. The immunoprecipitated DNA was released by proteinase K.
The DNA was eluted and diluted to a ﬁnal volume of 200 μl with nuclease-free
water. For each sample, an input vial was included using total sonicated DNA as
loading control. The primer sequences used for MeDIP/hMeDIP-qPCR cloning are
listed in Supplementary Table 3.
Glucosylation-mediated restriction enzyme sensitive PCR. The EpiMark Kit
(NEB, Ipswich, USA) was used to validate the conversion from 5′mC to 5′hmC at
the selected RASAL1 promoter region. The assay was performed according to the
manufacturer’s protocol. Brieﬂy, 10 µg of genomic DNA was used and equally
divided into two reactions, one treated with T4-phage βGT at 37 °C for 12 h, the
other one was kept as untreated control. Both the βGT-treated and untreated
samples were then divided into three PCR tubes and digested with either MspI,
HpaII, or left uncut at 37 °C for an additional 12 h. Samples were treated with
proteinase K at 40 °C for 10 min prior to dilution to a ﬁnal volume of 100 µl with
nuclease-free water and heating to 95 °C for 5 min. PCR was carried out in a
volume of 5 µl for each sample on a PCR cycler (Eppendorf, Hamburg, Germany)
with a standard PCR program. The primer sequences used for PCR are listed in
Supplementary Table 4. To visualize the PCR products, samples were loaded into
the Bioanalyzer 2100 electrophoresis system (Agilent Technologies, California,
USA). Electrophoresis results are shown as a virtual gel as previously described47.
Bisulﬁte sequencing. Puriﬁed cellular DNA was bisulﬁte-treated using the EZ
DNA Methylation-Lightning Kit (Zymoresearch, Irvine, USA) according to the
manufacture’s protocol. To amplify the Rasal1 and Kl promoter fragments, a
touchdown PCR program was performed using Taq DNA Polymerase (Sigma-
Aldrich, St. Louis, USA). The ﬁrst round of PCR consisted of the following cycling
conditions: 94 °C for 2 min, 6 cycles consisting of 30 s at 94 °C, 30 s at 60–55 °C
(reduce 1 °C after each cycle), and 30 s at 72 °C. The second round of PCR con-
sisted of the following cycling conditions: 32 cycles consisting of 30 s at 94 °C, 30 s
at 55 °C, and 30 s at 72 °C. The ﬁnal elongation consisted of 72 °C for 6 min. The
sequences of the PCR primers are listed in Supplementary Table 5. The PCR
products were puriﬁed using the QIAEX II Gel Extraction Kit (Qiagen, Hilden,
Germany), cloned into the pGEM-T Vector (Promega, Wisconsin, United States)
and transformed into Top10 Competent E.coli Cells (Life Technologies, Carlsbad,
USA). The plasmid DNA was then puriﬁed with DNA Plasmid Miniprep Kit
(Qiagen, Hilden, Germany) and sequenced (Seqlab, Göttingen, Germany).
Cell culture and transfection. TK173 and TK188 kidney ﬁbroblasts were isolated
from human kidney biopsies4. HEK293 and HK2 cells were purchased from ATCC
(Teddington, UK). Mouse kidney ﬁbroblasts were generated in our lab. Murine
Fig. 5 Targeted Rasal1 promoter demethylation by dCas9/dHFCas9-TET3CD-Rasal1-sgRNA fusion protein ameliorates kidney ﬁbrosis. a Schematic showing
the parenchymal injection of lentiviral particles containing dCas9/dHFCas9-TET3CD fusion protein into UUO-challenged kidneys. b Schedule of UUO
mouse surgery, lentivirus injection, and analysis. c qRT-PCR results showing that Rasal1 mRNA expression was signiﬁcantly induced in UUO-challenged
kidneys transduced with dCas9/dHFCas9-TET3CD-Rasal1-sgRNA, but not in UUO-challenged kidneys transduced with control dCas9/dHFCas9-TET3CD-
LacZ-sgRNA. There is no signiﬁcant difference between dCas9-TET3CD and dHFCas9-TET3CD constructs. Results were normalized to reference gene
Gapdh (expression is presented as mean value; error bars represent S.D., n≥ 5 in each group, # not signiﬁcant, ***p < 0.001). d Western blots showing
restored RASAL1 protein expression in UUO-challenged kidneys which were transduced with lentivirus expressing dCas9/dHFCas9-TET3CD-Rasal1-
sgRNA. The membranes were restriped and re-probed with α-TUBULIN antibody to serve as equal loading control. e, f UUO-challenged kidneys which
were transduced with lentivirus expressing dCas9/dHFCas9-TET3CD-Rasal1-sgRNA show signiﬁcantly reduced Rasal1 promoter methylation by MeDIP-
qPCR assay (e) and increased hydroxymethylation by hMeDIP-qPCR assay (f). There is no signiﬁcant difference between dCas9-TET3CD and dHFCas9-
TET3CD constructs. The results were calculated relative to input. The data are presented as mean value, error bars represent S.D., n≥ 5; # not signiﬁcant,
***p < 0.001. g Kidney sections from UUO- and sham-operated mice which were transduced with lentivirus expressing dCas9/dHFCas9-TET3CD-Rasal1-
sgRNA or dCas9/dHFCas9-TET3CD-LacZ-sgRNA were stained for Masson’s trichrome (MTS) (representative light microscopy images are shown in the
top row), Collagen-1 or α-SMA (representative confocal images are shown in the middle and bottom row, respectively) (Scale bars: 25 μm or 50 μm).
h–j Quantiﬁcation of the percentage of total interstitial ﬁbrosis and immunostained positive cells in each group is depicted (data are presented as mean
value, error bars represent S.E.M., n≥ 5 in each group, # not signiﬁcant, ***p < 0.001, ****p < 0.0001). Both dCas9-TET3CD and dHFCas9-TET3CD
lentivirus transduced UUO-operated kidneys show signiﬁcantly decreased interstitial ﬁbrosis level and a signiﬁcantly decreased number of α-SMA- and
Collagen-1-positive cells. HFCas9-TET3CD shows signiﬁcantly better efﬁcacies when compared to dCas9-TET3CD
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Fig. 6 Induction of Klotho promoter hydroxymethylation by dHFCas9-TET3CD-Klotho-sgRNA in tubular epithelial cells ameliorates kidney ﬁbrosis.
a Schematic shows retrograde ureter injection of lentiviral particles containing dHFCas9-TET3CD-Klotho-sgRNA into UUO-operated kidneys. b Schedule of
UUO mouse surgery, lentivirus injection, and analysis. c qRT-PCR results showing that Kl mRNA expression was signiﬁcantly induced in UUO-operated
kidneys transduced with dHFCas9-TET3CD-Kl-sgRNA but not in UUO-challenged kidneys transduced with LacZ-sgRNA control. Results were normalized to
reference gene Gapdh (expression is presented as mean value, error bars represent S.E.M., n= 6 in each group, ***p < 0.001). d UUO-operated kidneys
which were transduced with lentivirus expressing dHFCas9-TET3CD-Kl-sgRNA show signiﬁcantly reduced Kl promoter methylation level by MeDIP-qPCR
assay. The results were calculated relative to input. The data are presented as mean value, error bars represent S.D., n≥ 5, ***p < 0.001. e Kidney sections
from UUO- and sham-operated mice which were transduced with lentivirus expressing dHFCas9-TET3CD-Kl-sgRNA or LacZ-sgRNA were stained for
Masson’s trichrome (MTS) (representative light microscopy images are shown in the top row), Collagen-1 or α-SMA (representative confocal images are
shown in the middle and bottom row, respectively) (Scale bars: 25 μm or 50 μm). f–h Quantiﬁcation of the percentage of total interstitial ﬁbrosis and
immunostained positive cells in each group are depicted (data are presented as mean value, error bars represent S.E.M., n≥ 5 in each group, # not
signiﬁcant, *p < 0.05, **p < 0.01, ****p < 0.0001). UUO-challenged kidneys transduced with lentivirus expressing dHFCas9-TET3CD-Kl-sgRNA show
signiﬁcantly decreased interstitial ﬁbrosis level and a signiﬁcantly decreased number of α-SMA- and Collagen-1-positive cells
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MCT cells were kindly provided by Dr. Eric G. Neilson (Northwestern University,
Evanston, IL). Human TK188, HK2, HEK293, 293 T, MCT, and mKF (passages
between 3 and 5) were cultured in DMEM (Gibco, Carlsbad, USA) supplemented
with 2 mmol/l L-glutamine, 100 g/ml penicillin, 100 g/ml streptomycin and 10%
heat-inactivated fetal bovine serum (FBS, Cellgro, Manassas, USA) at 37 °C in 5%
CO2. For transfection experiments, cells were pre-plated and cultured overnight
and transfected with Lipofectamine 2000 (Life Technologies, Carlsbad, USA)
according to the manufacturer’s protocol. Brieﬂy, the plasmid DNA (2.5 μg each)
and Lipofectamine 2000 were mixed in a ratio of 1:2 in a total volume of 500 μl of
Opti-MEM (Life Technologies, Carlsbad, USA) and incubated at room temperature
to form complexes for 20 min. The transfection complex was added to the cells in
basic medium without serum. After overnight incubation, the medium was
replaced back to complete growth medium.
Chromatin immunoprecipitation-next genomic sequencing. ChIP assay was
performed using 1 Day ChIP kit and Shearing ChIP kit (Diagenode, Denville, USA)
according to the manufacturer’s protocol. After lentiviral transduction and cross-
linking, mouse kidney ﬁbroblasts were ﬁxed with formaldehyde and the DNA was
sheared into small fragments. After incubation with a Myc-tag antibody (Cell
signaling, Beverly, USA), the pulled-down complexes were de-crosslinked and
treated with proteinase K. The puriﬁed DNA samples were proceeded further for
library preparation by TruSeq RNA Library Prep Kit v2 (Illumina, USA) and
quality control and library validation were performed by Fragment Analyzer and
Kapa PCR (Illumina, USA), respectively. The fragments were sequenced by an
Illumina HiSeq4000 instrument. For data analysis, a previous established proto-
col48 was followed. Brieﬂy, the raw reads from two independent biological repli-
cates were ﬁrst concatenated and then peak calling was performed with MACSII in
order to obtain the count numbers. We used settings for narrow peaks (200 bp
window size, 200 bp gap size, and false discovery rate of 0.01) in all cases.
Virus packaging and titration. Lentiviruses were produced using 293 T virus
packaging cells upon transfection with a combination of 2nd Generation Packaging
System Mix (Abmgood, Richmond, Canada), pLenti-dCas9-TET3CD-sgRNA
(RASAL1, EYA1, LRFN2, KL, Rasal1, and Kl), and Lentifectin (Abmgood, Rich-
mond, Canada) according to the manufacture’s protocol. Lentiviral supernatant
was collected 2 and 3 days after transfection, ﬁltered through a 0.45 μm ﬁlter and
concentrated with Lenti-X Concentrator (Clonetech, Heidelberg, Germany). The
viral particles were resuspended in PBS and stored at −80 °C. Lentivirus titration
was determined by the Lenti-X qRT-PCR Titration Kit (Clonetech, Heidelberg,
Germany) and 8 μg/ml Polybrene (Sigma- Aldrich, Munich, Germany) was added
to the viral solution for the in vivo and in vitro transduction experiments.
Rasal1 mutant mouse production. Two different mouse embryonic stem cell
clones (A03, H03) carrying targeted gene knockout alleles were received from
EUCOMM international knockout mouse consortium. Stem cells were from the
JM8 line on a C57BL/6 N genetic background reference. The targeted Rasal1tm1a
(KOMP)WTSI allele carried a gene-trap DNA cassette, inserted into the second intron
of the gene, consisting of a splice acceptor site, an internal ribosome entry site, and
a β-galactosidase reporter. The use of the splice acceptor site is purposely to
generate a truncated non-functional transcript. After conﬁrming the correct gen-
ome targeting by long range PCR (Supplementary Fig. 12a), Rasal1 mutant ESCs
were injected into blastocysts to generate chimera mice which were further bred
with C57BL/6 N mice to generate Rasal1tm1a/+ mice. Homozygous Rasal1tm1a/ tm1a
mice were then generated by inbreeding (Supplementary Fig. 12b). Copy number
variation analysis of Rasal1tm1a mouse kidneys conﬁrmed that mutant mice carried
the correct copy number of gene-trap DNA cassette (Supplementary Fig. 12c). The
sequence of primers used for characterizing the Rasal1tm1a/+ mice are listed in
Supplementary Table 6. Mice were euthanized at 12–14 weeks of age under iso-
ﬂurane anesthesia with cervical dislocation. Tissues were rapidly harvested and
quick-frozen in liquid nitrogen, and stored at −80 °C. All animal work followed the
Guide of the Institutional Review Board of the University of Göttingen and the
responsible government authority of Lower Saxony (Germany).
Unilateral ureteral obstruction. All animal experiments complied with ethical
regulations and were conducted according to the animal experimental protocols
which were approved by the Institutional Review Board of the University of
Göttingen and the responsible government authority of Lower Saxony (Germany).
Eight-to-twelve-week-old wild-type C57BL/6 N mice were used for the study. After
anesthesia with isoﬂurane inhalation, analgesia was performed by subcutaneous
Buprenorphine injection. The ureter was separated from the surrounding tissues
and the left ureter was clamped distal to the infusion site by two ligatures14. The
abdominal muscles were sutured with absorbable suture, and the skin was closed
with non-absorbable suture49,50. Mice were sacriﬁced 10 days after ureter ligation
and viral solution injection. The UUO-operated and the contralateral kidney were
removed for histological analysis.
Intrarenal artery/vein infusion. After anesthesia, the aorta, inferior vena cava,
and the right renal vessels were visualized through a midline incision. After
completing the UUO surgery, the left renal artery/vein was clamped and the renal
artery/vein was cannulated with a 27-gauge needle. Either control LacZ-sgRNA or
Rasal1/Kl-sgRNA lentiviral solution (80 µl about 1 × 108 TUs) was slowly injected
under gentle pressure to avoid leaking of the injection solution. As the needle was
removed, a clamp was placed around the renal artery to trap the solution in the
kidney. Blood ﬂow was stopped for 15 min and then the clamps were removed,
thus restoring blood ﬂow to the kidney.
Retrograde ureteral infusion. Upon completion of the UUO surgery, the left
ureter-pelvic junction was cannulated with a 27-gauge needle. Viral solution (80 µl
about 1 × 108 TUs) was infused under gentle pressure to avoid renal pelvic dis-
tention and leaking of the viral solution.
Intraparenchymal injection. Once completing the UUO surgery, the left kidney
was locally injected with viral solution (80 µl about 1 × 108 TUs in total) into four
different sites.
Histology and Immunoﬂuorescence. Parafﬁn-embedded kidneys were sectioned
at 3 μm and Masson’s Trichrome Stain (MTS) was performed. We assessed the
ﬁbrotic area using CellSens (Olympus, Tokyo, Japan) software, as previously
described14. For immunoﬂuorescent staining, primary antibodies against α-smooth
muscle actin (1:100 diluted, Abcam, Cambridge, UK), Collagen-1 (1:100 diluted,
Abcam, Cambridge, UK), and Collagen-4 (1:100 diluted, BD/Pharmingen, San
Diego, USA), and Alexa Fluor 488, 568 (1:300 diluted, Life Technologies, USA,
Carlsbad, USA) secondary antibodies were used. Nuclear staining was performed
using 4′, 6-diamidino-2-phenylindole (DAPI, Vector Labs, Burlingame, USA).
Relative areas positive for α-SMA and Collagen-1 per visual ﬁelds were analyzed at
magniﬁcation × 40.
RNA extraction, cDNA synthesis, and real-time PCR analysis. Animal tissues
were shredded by TissueLyser LT (Qiagen, Hilden, Germany). Total RNA was
extracted from the shredded tissues or cells by direct lysis with TRIzol reagent (Life
Technologies, Carlsbad, USA) and RNA isolation was performed using the Pure-
Link RNA Mini Kit (Life Technologies, Carlsbad, USA) according to the manu-
facturer’s protocol. For ﬁrst-strand cDNA synthesis, 1 μg of total RNA was treated
with DNase I (Sigma- Aldrich, Munich, Germany) and then converted into
complementary DNA (cDNA) using the SuperScript II System (Life Technologies,
Carlsbad, USA). For qRT–PCR analysis, 2 μl of diluted cDNA (1:10) as a template
and the Fast SYBR Green Master Mix (Life Technologies, Carlsbad, USA) were
used in a ﬁnal volume of 20 μl for each reaction. Real-time PCR was performed in
triplicate in a 96-well format by StepOne Plus Real-Time PCR system (Life
Technologies, Carlsbad, USA). The real-time PCR primers are listed in Supple-
mentary Table 7. The relative expression levels were standardized to GAPDH using
2−ΔΔCt methods.
Western blot. Animal tissues were shredded by TissueLyser LT (Qiagen, Hilden,
Germany). The shredded tissues and cells were lysed in NP40 buffer (Life Tech-
nologies, Carlsbad, USA) containing protease inhibitor cocktail (Roche, Man-
nheim, Germany). Lysates were mixed with loading buffer and heated at 95 °C for
5 min. Protein samples were resolved on 4–12% SDS–PAGE gels (Life Technolo-
gies, Carlsbad, USA) and transferred onto nitrocellulose membranes (GE Health-
care, Freiburg, Germany). Non-speciﬁc antibody binding was blocked with 5%
nonfat milk in TBST buffer (50 mM Tris/150 mM NaCl/0.1% Tween-20) for 1 h.
The membranes were incubated with primary antibodies in incubation solution
(2% milk in TBST) overnight. Myc-tag antibody (Cell Signaling #5605, Danvers,
USA) was diluted 1:2500; Tubulin antibody (Sigma-Aldrich #T5168, Munich,
Germany) was diluted 1:5000; RASAL antibody (Abcam #ab168610, Cambridge,
UK; Biorbyt #orb101674, Cambridge, UK) was diluted 1:1000. The membranes
were washed three times with 2% milk in TBST and incubated with HRP con-
jugated secondary antibody for 1 h. Membranes were visualized using LumiGLO
chemiluminescence (Cell Signaling, Danvers, USA) and images were documented
by a ChemiDoc MP System and processed using ImageLab software (Bio-Rad,
Munich, Germany). All uncropped blots are included in Supplementary Fig. 13.
Statistical analysis. All qRT-PCR data for RNA expression analysis are presented
as the mean ± SD and represent a minimum of three independent experiments. As
for MeDIP-qPCR, two biological replicates with three technical replicates each
were analyzed, and the average of six values was used for further statistical analysis.
Histological analysis was assessed as 10 visual ﬁelds per mouse and average values
of each mouse were calculated. The average values for each mouse (n= 6) was then
used to calculate average per group. Statistical analysis was then performed on
these averages using One-way ANOVA with Bonferroni post-hoc analysis com-
paring selected pairs of columns.
Data availability. The authors declare that all relevant data supporting the ﬁndings
of this study are available within the paper and its supplementary information ﬁles.
All the ﬁgures and graphics were created by the authors. Complete ChIP-
sequencing data has been deposited in BioProject https://submit.ncbi.nlm.nih.gov/
subs/bioproject/SUB3776305/biosample with accession number [SUB3776305].
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